| Literature DB >> 34971376 |
Lisa A Lewis1, Sunita Gulati1, Wioleta M Zelek2, B Paul Morgan2, Wen-Chao Song3, Bo Zheng1, Nancy Nowak1, Rosane B DeOliveira1, Bryan Sanchez1, Leandro DeSouza Silva1, Janine Schuurman4, Frank Beurskens4, Sanjay Ram1, Peter A Rice1.
Abstract
A safe and effective vaccine against multidrug-resistant gonorrhea is urgently needed. An experimental peptide vaccine called TMCP2 that mimics an oligosaccharide epitope in gonococcal lipooligosaccharide, when adjuvanted with glucopyranosyl lipid adjuvant-stable emulsion, elicits bactericidal immunoglobulin G and hastens clearance of gonococci in the mouse vaginal colonization model. In this study, we show that efficacy of TMCP2 requires an intact terminal complement pathway, evidenced by loss of activity in C9-/- mice or when C7 function was blocked. In conclusion, TMCP2 vaccine efficacy in the mouse vagina requires membrane attack complex. Serum bactericidal activity may serve as a correlate of protection for TMCP2.Entities:
Keywords: zzm321990 Neisseria gonorrhoeaezzm321990 ; complement; gonorrhea; lipooligosaccharide; terminal complement pathway; vaccine
Mesh：
Substances：
Year: 2022 PMID： 34971376 PMCID： PMC9113499 DOI： 10.1093/infdis/jiab630
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 7.759